Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2021 | Evolution of multiple myeloma treatment in Norway

Fredrik Schjesvold • 1 Apr 2021
ESH MM 2021
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide

Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, outlines the evolution of multiple myeloma treatment in Norway. Dr Schjesvold highlights use of the lenalidomide, bortezomib and dexamethasone triplet in the first-line setting, as well as discussing the uptake of various diagnostic tools to improve multiple myeloma treatment. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.

More from Fredrik Schjesvold

1:29
Replacing dexamethasone in transplant-ineligible multiple myeloma: the REST study
Fredrik Schjesvold • 11 Dec 2023
1:21
The REMNANT study: will treating patients at MRD relapse improve survival outcomes?
Fredrik Schjesvold • 11 Dec 2023
1:38
A Phase I study of WVT078, a BCMA×CD3 bsAb, with a gamma-secretase inhibitor (WHG626) in R/R MM
Fredrik Schjesvold • 11 Dec 2023
1:23
Melflufen/dex versus pom/dex in patients with R/R multiple myeloma without previous transplant
Fredrik Schjesvold • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals